Base de dados : MEDLINE
Pesquisa : D13.444.600.223.550 [Categoria DeCS]
Referências encontradas : 148 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 15 ir para página                         

  1 / 148 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:25633445
[Au] Autor:Bolarinwa RA; Oyekunle AA; Arogundade FA; Sanusi AA; Salawu L; Togun RA; Akinola NO; Durosinmi MA; Akinsola AA
[Ad] Endereço:Department of Haematology and Immunology, Obafemi Awolowo University and Obafemi Awolowo University Teaching Hospitals Complex, Ile-Ife, Nigeria.
[Ti] Título:Preliminary report of HLA (DNA) typing of Nigerians using sequence-specific primer technique.
[So] Source:Niger Postgrad Med J;21(4):285-9, 2014 Dec.
[Is] ISSN:1117-1936
[Cp] País de publicação:Nigeria
[La] Idioma:eng
[Ab] Resumo:AIMS AND OBJECTIVES: This communication is an attempt to present the experience and a preliminary report of results over a one-year period. PATIENTS AND METHODS: From December 2011 to December 2012, a prospective determination of the HLA types of 20 individuals referred to the Tissue Typing Laboratory of the Obafemi Awolowo University Teaching Hospitals Complex (OAUTHC), Ile-Ife was done. These consisted of prospective transplant recipients, their donors, and a migrant pair for kinship determination. DNA was extracted from the client's peripheral blood sample, using the QIAmp Blood DNA Mini kit, (Qiagen). PCR was done using OlerupR low-resolution PCR-SSP typing kit. The PCR product was resolved in 2% agarose gel, and the bands visualised under UV light. The HLA types were determined using provided tables and/or Helmberg software. Data were presented using descriptive statistics whileHLA antigen frequency (AF) was expressed in percentage and gene frequency (GF) was determined using square root method (1-(1-AF)1/2). RESULTS: A total of 20 individuals (13males and 7females) consisting of seven renal transplant recipients and seven prospective donors; a stem cell recipient and three donors and a migrant pair for kinship determination were typed. Age ranged from 4-65 years. 44 HLA alleles were detected, while HLA-A, B, C, DRB1 and DQB1 were 7, 10, 11, 8, 8 alleles respectively. The alleles were heterogeneous in distribution while 6 antigens (HLA-A*02, B*30, C*15, DRB1*03, DRB1*08 and DQB1*06) were having frequencies e"25%. CONCLUSION: This report confirms that DNA-based HLA typing is feasible locally, andit was observed that renal transplantation procedure is the most frequent indication. The HLA antigens observed to have very high frequencies (e"25% frequency) in this population were HLA-A*02, B*30, C*15, DRB1*03, DRB1*08 and DQB1*06. There is a strong need to develop a broad-based HLA data bank for Nigeria to further strengthening her transplantation programmes.
[Mh] Termos MeSH primário: Impressões Digitais de DNA/métodos
Sondas de DNA de HLA/análise
Teste de Histocompatibilidade/métodos
Transplante de Órgãos
Doadores de Tecidos/estatística & dados numéricos
Transplantados/estatística & dados numéricos
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Alelos
Criança
Pré-Escolar
Feminino
Frequência do Gene
Seres Humanos
Masculino
Meia-Idade
Nigéria
Estudos Prospectivos
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (DNA Probes, HLA)
[Em] Mês de entrada:1509
[Cu] Atualização por classe:150130
[Lr] Data última revisão:
150130
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150131
[St] Status:MEDLINE


  2 / 148 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:22443801
[Au] Autor:Testi M; Battarra M; Troiano M; Condello R; Andreani M
[Ad] Endereço:Laboratory of Immunogenetics and Transplant Biology, IME Foundation at Polyclinic of Tor Vergata, Rome, Italy. manuela.testi@libero.it
[Ti] Título:Characterization of the novel HLA-C*07:195 allele in an Italian hematopoietic stem cell volunteer donor, detected by sequence-based typing.
[So] Source:Tissue Antigens;80(1):67-8, 2012 Jul.
[Is] ISSN:1399-0039
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The new allele shows one nucleotide change from C*07:02:01:01 at 351 nt from C to A, resulting in an amino acid change at codon 93 of exon 3 from H to Q.
[Mh] Termos MeSH primário: Alelos
Éxons/genética
Antígenos HLA-C/genética
Mutação/genética
[Mh] Termos MeSH secundário: Sequência de Aminoácidos
Sondas de DNA de HLA/genética
Transplante de Células-Tronco Hematopoéticas
Teste de Histocompatibilidade
Seres Humanos
Itália
Dados de Sequência Molecular
Polimorfismo de Nucleotídeo Único
Análise de Sequência de DNA
Doadores de Tecidos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (DNA Probes, HLA); 0 (HLA-C Antigens)
[Em] Mês de entrada:1210
[Cu] Atualização por classe:120601
[Lr] Data última revisão:
120601
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:120327
[St] Status:MEDLINE
[do] DOI:10.1111/j.1399-0039.2012.01866.x


  3 / 148 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:22259780
[Au] Autor:Woo HI; Joo EY; Hong SB; Lee KW; Kang ES
[Ad] Endereço:Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
[Ti] Título:Use of PCR with sequence-specific primers for high-resolution human leukocyte antigen typing of patients with narcolepsy.
[So] Source:Ann Lab Med;32(1):57-65, 2012 Jan.
[Is] ISSN:2234-3814
[Cp] País de publicação:Korea (South)
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Narcolepsy is a neurologic disorder characterized by excessive daytime sleepiness, symptoms of abnormal rapid eye movement (REM) sleep, and a strong association with HLA-DRB1*1501, -DQA1*0102, and -DQB1*0602. Here, we investigated the clinico-physical characteristics of Korean patients with narcolepsy, their HLA types, and the clinical utility of high-resolution PCR with sequence-specific primers (PCR-SSP) as a simple typing method for identifying DRB1*15/16, DQA1, and DQB1 alleles. METHODS: The study population consisted of 67 consecutively enrolled patients having unexplained daytime sleepiness and diagnosed narcolepsy based on clinical and neurological findings. Clinical data and the results of the multiple sleep latency test and polysomnography were reviewed, and HLA typing was performed using both high-resolution PCR-SSP and sequence-based typing (SBT). RESULTS: The 44 narcolepsy patients with cataplexy displayed significantly higher frequencies of DRB1*1501 (Pc= 0.003), DQA1*0102 (Pc=0.001), and DQB1*0602 (Pc=0.014) than the patients without cataplexy. Among patients carrying DRB1*1501-DQB1*0602 or DQA1*0102, the frequencies of a mean REM sleep latency of less than 20 min in nocturnal polysomnography and clinical findings, including sleep paralysis and hypnagogic hallucination were significantly higher. SBT and PCR-SSP showed 100% concordance for high-resolution typing of DRB1*15/16 alleles and DQA1 and DQB1 loci. CONCLUSIONS: The clinical characteristics and somnographic findings of narcolepsy patients were associated with specific HLA alleles, including DRB1*1501, DQA1*0102, and DQB1*0602. Application of high-resolution PCR-SSP, a reliable and simple method, for both allele- and locus-specific HLA typing of DRB1*15/16, DQA1, and DQB1 would be useful for characterizing clinical status among subjects with narcolepsy.
[Mh] Termos MeSH primário: Sondas de DNA de HLA
Teste de Histocompatibilidade
Narcolepsia/diagnóstico
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Alelos
Cataplexia/genética
Feminino
Frequência do Gene
Predisposição Genética para Doença
Genótipo
Antígenos HLA-DQ/genética
Cadeias HLA-DRB1/genética
Seres Humanos
Masculino
Meia-Idade
Narcolepsia/genética
Fenótipo
Reação em Cadeia da Polimerase
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (DNA Probes, HLA); 0 (HLA-DQ Antigens); 0 (HLA-DRB1 Chains)
[Em] Mês de entrada:1205
[Cu] Atualização por classe:150128
[Lr] Data última revisão:
150128
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:120120
[St] Status:MEDLINE
[do] DOI:10.3343/alm.2012.32.1.57


  4 / 148 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:21299532
[Au] Autor:Lebedeva TV; Mastromarino SA; Lee E; Ohashi M; Alosco SM; Yu N
[Ad] Endereço:HLA Laboratory, American Red Cross Blood Services, New England Region, Dedham, MA 02026, USA. LebedevaT@usa.redcross.org
[Ti] Título:Resolution of HLA class I sequence-based typing ambiguities by group-specific sequencing primers.
[So] Source:Tissue Antigens;77(3):247-50, 2011 Mar.
[Is] ISSN:1399-0039
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The increasing demand for allele-level human leukocyte antigen (HLA) typing has led the sequence-based typing (SBT) to become the preferred method. In turn, the steady increase in the number of HLA alleles driven by the adoption of SBT as the ultimate typing method leads to the ever increasing number of cis/trans ambiguities. Over the last few years, additional sequencing with the commercially available group-specific sequencing primers (GSSPs) has replaced sequence-specific primer-polymerase chain reaction and group-specific amplification as the means of resolving cis/trans ambiguities in many laboratories. Here we summarize our 3-year experience in designing and utilizing GSSPs for resolution of HLA class I ambiguities. The panel of GSSPs used in our laboratory includes 14 primers for HLA-A, 18 for HLA-B, and 13 primers for HLA-C. The panel resolves 99.9% of all ambiguities.
[Mh] Termos MeSH primário: Primers do DNA
Genes MHC Classe I/genética
Teste de Histocompatibilidade/métodos
Análise de Sequência de DNA/normas
[Mh] Termos MeSH secundário: Alelos
Sequência de Bases
Primers do DNA/genética
Sondas de DNA de HLA/análise
Sondas de DNA de HLA/genética
Reações Falso-Positivas
Seres Humanos
Dados de Sequência Molecular
Estudos Retrospectivos
Análise de Sequência de DNA/métodos
Homologia de Sequência
Software
Especificidade por Substrato/genética
Especificidade por Substrato/imunologia
[Pt] Tipo de publicação:EVALUATION STUDIES; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (DNA Primers); 0 (DNA Probes, HLA)
[Em] Mês de entrada:1106
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:110209
[St] Status:MEDLINE
[do] DOI:10.1111/j.1399-0039.2010.01616.x


  5 / 148 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:21155086
[Au] Autor:García-Corona C; Vega-Memije E; Barquera R; Granados J
[Ad] Endereço:Department of Dermatology, Hospital General Dr. Manuel Gea González, México City, Mexico. itzamma@hotmail.com
[Ti] Título:HLA-DR alleles associated with skin warts induced by human papillomavirus infection.
[So] Source:Int J Dermatol;49(12):1376-9, 2010 Dec.
[Is] ISSN:1365-4632
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The skin wart is a benign proliferation of the skin and mucous, secondary to human papillomavirus (HPV) infection. OBJECTIVES: The objective of this study is to determine gene frequencies of HLA-DR alleles in Mexican patients with skin warts and compare them with those present in ethnically matched healthy subjects. METHODS: Fifty-two patients with clinically and histologically confirmed skin warts from the Dermatology Outpatient Clinic, with results of high-resolution DNA typing for HLA-DR polymorphism. RESULTS: HLA-DR3 and DR9 were increased (P = 0.0029, OR: 2.5, 95% CI: 1.3­4.7 and P = 0.0062, OR: 5.4, 95% CI: 1.4­19.5, respectively), and HLA-DR6 allele was found decreased (P = 0.0002). LIMITATIONS: The major histocompatibility complex contribution in the infection and elimination of the virus is not clear and perhaps also contributes to a series of events not well established yet. CONCLUSIONS: This study follows the preponderant role of class II genes in the susceptibility or resistance to the development of skin warts caused by HPV infection.
[Mh] Termos MeSH primário: Frequência do Gene
Genes MHC Classe II
Antígenos HLA-DR/genética
Infecções por Papillomavirus/genética
Verrugas/genética
[Mh] Termos MeSH secundário: Adolescente
Adulto
Alelos
Criança
Pré-Escolar
Sondas de DNA de HLA
Feminino
Predisposição Genética para Doença
Seres Humanos
Masculino
México
Meia-Idade
Papillomaviridae
Polimorfismo Genético
Verrugas/virologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (DNA Probes, HLA); 0 (HLA-DR Antigens)
[Em] Mês de entrada:1103
[Cu] Atualização por classe:101208
[Lr] Data última revisão:
101208
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:101215
[St] Status:MEDLINE


  6 / 148 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:20976932
[Au] Autor:Fukushima N
[Ad] Endereço:Division of Molecular Pharmaceutical Science, Department of Pharmacology, Osaka University Graduate School of Medicine.
[Ti] Título:[Organ transplantation and genetic testing].
[So] Source:Nihon Rinsho;68 Suppl 8:568-74, 2010 Aug.
[Is] ISSN:0047-1852
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Mh] Termos MeSH primário: Testes Genéticos/métodos
Transplante de Órgãos
[Mh] Termos MeSH secundário: Sondas de DNA de HLA
Antígenos HLA/análise
Seres Humanos
Infecção/diagnóstico
Transtornos Linfoproliferativos/diagnóstico
Complicações Pós-Operatórias/diagnóstico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (DNA Probes, HLA); 0 (HLA Antigens)
[Em] Mês de entrada:1012
[Cu] Atualização por classe:110727
[Lr] Data última revisão:
110727
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:101028
[St] Status:MEDLINE


  7 / 148 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:20403144
[Au] Autor:Chainonthee W; Böttcher G; Gagne K; Füssel M; Bignon JD; Wassmuth R
[Ad] Endereço:Medizinische Klinik u. Poliklinik I, Universitätsklinikum Carl Gustav Carus der Technischen Universität Dresden, Dresden, Germany.
[Ti] Título:Improved KIR gene and HLA-C KIR ligand sequence-specific primer polymerase chain reaction genotyping using whole genome amplification.
[So] Source:Tissue Antigens;76(2):135-43, 2010 Aug.
[Is] ISSN:1399-0039
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Molecular analysis of genetic polymorphism for clinical or research purposes may be compromised by genomic DNA of limited quality and quantity. In this study, we have successfully tested the feasibility of using whole genome amplification (WGA) to allow genotyping for killer cell immunoglobulin-like receptor (KIR) genes and human leucocyte antigen (HLA)-C KIR ligand dimorphism on HLA-C. WGA was achieved by multiple displacement amplification (MDA) using bacteriophage phi29 polymerase. For KIR genotyping, a revised sequence-specific primer polymerase chain reaction protocol consisting of 23 primer pairs was used avoiding hitherto undetected cross-priming involving KIR2DL1, KIR2DS1, KIR3DL1 and KIR3DS1 alleles. Similarly, MDA-amplified genomic DNA was analyzed for the detection of the HLA-C KIR ligand groups C1 and C2, based on the amino acid K/N dimorphism in position 80.
[Mh] Termos MeSH primário: Antígenos HLA-C/genética
Reação em Cadeia da Polimerase/métodos
Receptores KIR/genética
[Mh] Termos MeSH secundário: Alelos
Sequência de Bases
Primers do DNA/genética
Sondas de DNA de HLA/genética
Estudo de Associação Genômica Ampla
Genótipo
Seres Humanos
Ligantes
Polimorfismo de Nucleotídeo Único
Receptores KIR2DL1/genética
Receptores KIR3DL1/genética
Receptores KIR3DS1/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (DNA Primers); 0 (DNA Probes, HLA); 0 (HLA-C Antigens); 0 (KIR2DL1 protein, human); 0 (KIR2DS1 protein, human); 0 (KIR3DL1 protein, human); 0 (Ligands); 0 (Receptors, KIR); 0 (Receptors, KIR2DL1); 0 (Receptors, KIR3DL1); 0 (Receptors, KIR3DS1)
[Em] Mês de entrada:1012
[Cu] Atualização por classe:100728
[Lr] Data última revisão:
100728
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:100421
[St] Status:MEDLINE
[do] DOI:10.1111/j.1399-0039.2010.01479.x


  8 / 148 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:19761370
[Au] Autor:Andrade RJ; Robles M; Ulzurrun E; Lucena MI
[Ad] Endereço:Unidad de Hepatología, Departamento de Medicina, Facultad de Medicina, Boulevard Louis Pasteur 32, 29071 Málaga, Spain. andrade@uma.es
[Ti] Título:Drug-induced liver injury: insights from genetic studies.
[So] Source:Pharmacogenomics;10(9):1467-87, 2009 Sep.
[Is] ISSN:1744-8042
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Drug-induced liver injury (DILI) is an increasing health problem and a challenge for physicians, regulatory bodies and the pharmaceutical industry, not only because of its potential severity and elusive pathogenesis but also because it is often inaccurately diagnosed, commonly missed entirely and more often not reported. The general view is that idiosyncratic DILI, which is not predictable whether based on the pharmacology of the drug or on the dose administered, is determined by the presence in the recipient of variants in, or expression of, genes coding for key metabolic pathways and/or the immune response, and the interaction of these genetic variants with environmental variables. Furthermore, idiosyncratic DILI is an example of a complex-trait disease with two or more susceptibility loci, as reflected by the frequency of genetic variants in the population often being higher than the occurrence of significant liver injury. Polymorphisms of bioactivation/toxification pathways via the CYP450 enzymes (Phase I), detoxification reactions (Phase II) and excretion/transport (Phase III), together with immunological factors that might determine DILI are reviewed. Challenges such as gene-trait association studies and whole-genome studies, and future approaches to the study of DILI are explored. Better knowledge of the candidate genes involved could provide further insight for the prospective identification of susceptible patients at risk of developing drug-induced hepatotoxicity, development of new diagnostic tools and new treatment strategies with safer drugs.
[Mh] Termos MeSH primário: Doença Hepática Induzida por Substâncias e Drogas/genética
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos
[Mh] Termos MeSH secundário: Biotransformação/genética
Doença Hepática Induzida por Substâncias e Drogas/diagnóstico
Doença Hepática Induzida por Substâncias e Drogas/enzimologia
Doença Hepática Induzida por Substâncias e Drogas/imunologia
Sistema Enzimático do Citocromo P-450/genética
Sondas de DNA de HLA
Hipersensibilidade a Drogas/genética
Estudo de Associação Genômica Ampla
Seres Humanos
Estresse Oxidativo/genética
Fatores de Risco
Sulfóxidos/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (DNA Probes, HLA); 0 (Sulfoxides); 9035-51-2 (Cytochrome P-450 Enzyme System)
[Em] Mês de entrada:0911
[Cu] Atualização por classe:161125
[Lr] Data última revisão:
161125
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:090919
[St] Status:MEDLINE
[do] DOI:10.2217/pgs.09.111


  9 / 148 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:18031478
[Au] Autor:Schreuder TC; Gelderblom HC; Weegink CJ; Hamann D; Reesink HW; Devries JH; Hoekstra JB; Jansen PL
[Ad] Endereço:Department of Gastroenterology and Hepatology, AMC Liver Centre, University of Amsterdam, Amsterdam, The Netherlands. t.c.schreuder@amc.uva.nl
[Ti] Título:High incidence of type 1 diabetes mellitus during or shortly after treatment with pegylated interferon alpha for chronic hepatitis C virus infection.
[So] Source:Liver Int;28(1):39-46, 2008 Jan.
[Is] ISSN:1478-3231
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Development of diabetes mellitus (DM) during or shortly after treatment with interferon alpha (IFN-alpha) in patients with chronic hepatitis C virus (HCV) infection has been reported sporadically. We prospectively screened for DM during and after IFN-alpha therapy for chronic HCV infection. METHODS: Blood glucose levels of patients with chronic HCV infection were routinely assessed at all outpatient visits during and after treatment with pegylated-IFN-alpha (Peg-IFN-alpha) and ribavirin (Riba). RESULTS: Between December 2002 and October 2005, 189 non-diabetic patients were treated with Peg-IFN-alpha/Riba, of whom five developed type 1 DM (2.6%), three type 2 DM (1.6%) and one an indeterminate type of DM. Classical symptoms of DM were present in three patients who developed DM shortly after cessation of Peg-IFN-alpha/Riba. In the other patients, symptoms of DM were either indistinguishable from side effects caused by Peg-IFN-alpha/Riba or absent. CONCLUSION: Our study showed a high incidence of type 1 DM during Peg-IFN-alpha/Riba therapy for chronic HCV infection. Symptoms of DM may be absent or mistaken for Peg-IFN-alpha/Riba-associated side effects. To diagnose DM without delay, we propose routine assessment of blood glucose at all outpatient visits during and after Peg-IFN-alpha/Riba treatment in chronic HCV patients.
[Mh] Termos MeSH primário: Diabetes Mellitus Tipo 1/etiologia
Hepatite C Crônica/tratamento farmacológico
Interferon-alfa/efeitos adversos
Polietilenoglicóis/efeitos adversos
Ribavirina/efeitos adversos
[Mh] Termos MeSH secundário: Glicemia/análise
Peptídeo C/sangue
Sondas de DNA de HLA
Feminino
Seres Humanos
Interferon-alfa/uso terapêutico
Masculino
Polietilenoglicóis/uso terapêutico
Proteínas Recombinantes
Ribavirina/uso terapêutico
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Blood Glucose); 0 (C-Peptide); 0 (DNA Probes, HLA); 0 (Interferon-alpha); 0 (Recombinant Proteins); 30IQX730WE (Polyethylene Glycols); 47RRR83SK7 (interferon alfa-2a); 49717AWG6K (Ribavirin); Q46947FE7K (peginterferon alfa-2a)
[Em] Mês de entrada:0803
[Cu] Atualização por classe:161124
[Lr] Data última revisão:
161124
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:071123
[St] Status:MEDLINE


  10 / 148 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:18018760
[Au] Autor:Hammond E; Almeida CA; Mamotte C; Nolan D; Phillips E; Schollaardt TA; Gill MJ; Angel JB; Neurath D; Li J; Giulivi T; McIntyre C; Koultchitski G; Wong B; Reis M; Rachlis A; Cole DE; Chew CB; Neifer S; Lalonde R; Roger M; Jeanneau A; Mallal S
[Ad] Endereço:Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Western Australia, Australia. E.Hammond@murdoch.edu.au
[Ti] Título:External quality assessment of HLA-B*5701 reporting: an international multicentre survey.
[So] Source:Antivir Ther;12(7):1027-32, 2007.
[Is] ISSN:1359-6535
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: HLA-B*5701 strongly predicts abacavir hypersensitivity (HSR), but implementation of effective routine screening into clinical practice requires testing be practical and accurate. We tested the proficiency of HLA-B*5701 typing among laboratories using sequence-specific primer PCR. DESIGN AND METHODS: DNA panels (1 and 2) were distributed to seven laboratories (A to G) for blinded typing of the HLA-B*5701 allele. Panel 1 (n = 10 samples; n = 7 laboratories) included 3 positives and other closely related B17 subtypes (B*5702, B*5703, B*5704 and B*5801). Panel 2 (n = 96 samples; n = 4 laboratories) included 36 positives among a broad spectrum of other B alleles. Two laboratories (A and B) also submitted 96 routine samples, typed by the same methodology, to the reference centre for additional analysis by sequence-based typing. RESULTS: All laboratories correctly typed panel 1 for HLA-B*5701 carriage. Laboratories A, B and C identified HLA-B*5701 alleles in panel 2 with 100% sensitivity and 100% specificity. Laboratory D reported one false negative, reportedly due to a sampling error. The results obtained for routine samples typed by laboratories A and B and those generated by the reference laboratory using sequencing were fully concordant. CONCLUSIONS: Detection of HLA-B*5701 alleles among laboratories was 100% specific and 99.4% sensitive, indicating that participating HIV testing laboratories were currently offering effective primary screening to identify individuals at high risk of abacavir HSR. Accurate reporting of HLA-B*5701 status is critical for the safe administration of this drug and participation in quality assurance programmes by all sites who report HLA-B*5701 status should be promoted.
[Mh] Termos MeSH primário: Didesoxinucleosídeos/efeitos adversos
Testes Genéticos/normas
Antígenos HLA-B/genética
[Mh] Termos MeSH secundário: Alelos
Fármacos Anti-HIV/efeitos adversos
Fármacos Anti-HIV/uso terapêutico
Primers do DNA
Sondas de DNA de HLA
Didesoxinucleosídeos/uso terapêutico
Hipersensibilidade a Drogas/genética
Seres Humanos
Reação em Cadeia da Polimerase
Controle de Qualidade
Reprodutibilidade dos Testes
Sensibilidade e Especificidade
[Pt] Tipo de publicação:EVALUATION STUDIES; JOURNAL ARTICLE; MULTICENTER STUDY; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Anti-HIV Agents); 0 (DNA Primers); 0 (DNA Probes, HLA); 0 (Dideoxynucleosides); 0 (HLA-B Antigens); 0 (HLA-B*57:01 antigen); WR2TIP26VS (abacavir)
[Em] Mês de entrada:0712
[Cu] Atualização por classe:130524
[Lr] Data última revisão:
130524
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:071121
[St] Status:MEDLINE



página 1 de 15 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde